Scott Vanappledorn, MD
Urology · Kirkland, WANPI 1215923479
Payments from drug & device makers
Across 24 payments — averaging $25.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$108
- Procept Biorobotics Corporation$88
- 180 Medical, Inc.$58
- Sumitomo Pharma America, Inc.$56
- Progenics Pharmaceuticals, Inc.$54
- Coloplast$52
- plus $201 from 7 others
What the payments were for
- Food & beverage$617100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 3 | $108 |
| Procept Biorobotics Corporation | 3 | $88 |
| 180 Medical, Inc. | 2 | $58 |
| Sumitomo Pharma America, Inc. | 2 | $56 |
| Progenics Pharmaceuticals, Inc. | 2 | $54 |
| Coloplast | 2 | $52 |
| Johnson & Johnson(2 entities) | 2 | $51 |
| Tolmar Pharmaceuticals, Inc. | 2 | $41 |
| Myovant Sciences Inc. | 2 | $34 |
| EDAP Technomed Inc | 1 | $25 |
| Laborie Medical Technologies Corp. | 1 | $19 |
| Olympus America Inc. | 1 | $16 |
| Amgen | 1 | $15 |
How this compares
$617 in reported general payments places this provider in the 30th percentile of 274 urology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 71 | $49,011 |
| Mirabegron ErMirabegron | 17 | $8,233 |
| Tamsulosin Hcl | 625 | $7,065 |
| Finasteride | 480 | $6,048 |
| Tadalafil | 17 | $937 |
| Dutasteride | 29 | $913 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 57 | $626 |
| Doxazosin Mesylate | 19 | $550 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 29 | $250 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 26 | $169 |
| Oxybutynin Chloride | 11 | $149 |
| Oxycodone Hcl | 55 | $118 |
| Cephalexin | 23 | $109 |
| Levofloxacin | 69 | $82 |
| WaterWater For Irrigation,sterile | 12 | $40 |
Paid to pharmacies, not to this prescriber.
Other urology in Kirkland
- Kevin OstrowskiKirkland$64K
- Sabrina StairKirkland$9K
- James PorterSeattle$2.6M
- Shane PearceSpokane$1.8M
- Raymond LanceSpokane$1.2M
- Jonathan WrightSeattle$1M
- Thomas WalshSeattle$388K
- Una LeeSeattle$236K
- Marah HehemannSeattle$213K
- Sarah PsutkaSeattle$185K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.